Global Musculoskeletal Partnering Deals Report 2023: Comprehensive Access to 600+ Available Deals and Contract Documents

2023-06-02
PRNewswire
细胞疗法
DUBLIN, June 2, 2023 /PRNewswire/ -- The "Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to
ResearchAndMarkets.com's offering.
This report provides the full collection of musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
Trends in musculoskeletal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Musculoskeletal partnering agreement structure
Musculoskeletal partnering contract documents
Top musculoskeletal deals by value
Most active musculoskeletal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals.
The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.
Global Musculoskeletal Partnering 2016 to 2023 includes:
Trends in musculoskeletal dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of musculoskeletal deal contract documents
Comprehensive access to over 600 musculoskeletal deal records
The leading musculoskeletal deals by value since 2016
Most active musculoskeletal dealmakers since 2016
In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in musculoskeletal dealmaking
2.1. Introduction
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication
Chapter 3 -Financial deal terms for musculoskeletal partnering
3.1. Introduction
3.2. Disclosed financials terms for musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates
Chapter 4 - Leading musculoskeletal deals and dealmakers
4.1. Introduction
4.2. Most active in musculoskeletal partnering
4.3. List of most active dealmakers in musculoskeletal
4.4. Top musculoskeletal deals by value
Chapter 5 - Musculoskeletal contract document directory
5.1. Introduction
5.2. Musculoskeletal partnering deals where contract document available
Chapter 6 - Musculoskeletal dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by musculoskeletal therapeutic target
Companies Mentioned
3D-Side
Aavis Pharmaceuticals
Abarca
Accenture
Activbody
Active Implants
Adaptive Health
Advanced Human Imaging
AKL Research and Development
Allergan
Almirall
American Association of Neuromuscular & Electrodiagnostic Medicine
Analysis Group
Angers University
Apple
Apsen Farmacutica
Aptahem
ARK Crystal
Arthrex
Athrotech
Australian Research Council
Autotelic BIO
AWB Schraubtechnik und Industriebedarf
Back-A-Line
Baebies
Bauerfeind
Bayer
Bazis NN
BC Platforms
Berg
BGI
Biocomposites
BioMed X Innovation Center
BioPharma Forest
Bioservo Technologies
Biosolution
Bison & Rose
Blueprint Medicines
Bodycad
BRM Extremities
c-LEcta
California Institute for Regenerative Medicine
Calimmune
Cantargia
CareFirst BlueCross BlueShield
Cartiva
CAS
cbdMD
Cellthera Pharma
Cell Therapy Catapult
Celltrion
Centinel Spine
Cerhum
For more information about this report visit https://www.researchandmarkets.com/r/f6nnrt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。